Clinical use of calcium entry blockers

Area of Science:

• Cardiology
• Pharmacology

Background:

• Coronary vasospasm is increasingly recognized as a cause of myocardial ischemic pain in patients with coronary atherosclerosis.
• This vasospasm, affecting 27-35% of patients with angina at rest, is triggered by normal stimuli leading to coronary artery spasm.
• Evidence suggests increased intracellular calcium release from sarcolemmal sites may cause this spasm.

Purpose of the Study:

• To investigate the mechanisms by which calcium entry blockers prevent coronary vasospasm.
• To compare the distinct mechanisms of action of verapamil and diltiazem in reducing intracellular calcium.
• To highlight the differential effects of these agents on cardiac function and their suitability for various clinical conditions.

Main Methods:

• The study reviews existing evidence on the role of calcium in coronary vasospasm.
• It analyzes the pharmacological actions of calcium entry blockers, specifically verapamil and diltiazem.
• Comparative analysis of their effects on intracellular calcium levels, sarcolemmal stores, and ion transport mechanisms.

Main Results:

• Calcium entry blockers are effective in preventing coronary spasm by reducing intracellular calcium.
• Verapamil directly reduces intracellular and sarcolemmal calcium stores.
• Diltiazem reduces intracellular calcium by stimulating the sodium-potassium pump, enhancing sodium-calcium exchange.

Conclusions:

• Verapamil and diltiazem employ different mechanisms to combat coronary vasospasm.
• Their distinct effects on myocardial contractility, cardiac conduction, and vascular smooth muscle influence their clinical applications.
• These differences make specific calcium entry blockers more suitable for treating conditions like angina, tachycardia, hypertension, and hypertrophic cardiomyopathy.